Two-year data support Bayer's Eylea with T&E dosing regimens in wet AMD

9 September 2019
eylea-big

German pharma major Bayer (BAYN: DE) has announced two-year data which reconfirm the use of proactive Treat and Extend (T&E) dosing regimens with Eylea (aflibercept) solution for intravitreal injection for patients with wet age-related macular degeneration (wet AMD).

This includes data from the Phase IIIb/IV ARIES study,as well as results from an indirect comparison of published randomized clinical trials in wet AMD on either the anti-VEGF treatments aflibercept or ranibizumab.The study results were presented at the 19th Congress of the European Society of Retina Specialists (EURETINA) in Paris, France.

Eylea is one of Bayer’s top-selling drugs, generating sales of 604 million euros ($667 million) in the second quarter of 2019, up 11.9% on the like year-earlier period.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical